U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. AURA3: Hand-foot syndrome
  1. Section N/A

AURA3: Hand-foot syndrome

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, what was the SEVERITY of your Hand-Foot Syndrome at its WORST?"

Patients scored the severity of their Hand-Foot Syndrome on a 5-point scale (None, Mild, Moderate, Severe, Very Severe)

All Patients Who Completed the Questionnaire Described Their Experience of Hand-Foot Syndrome During the First 24 Weeks on Treatment:

Figure 1 shows the percentage of patients reporting the severity of their Hand-Foot Syndrome at each time point. For example, at week 2, 30% of patients taking Tagrisso reported Hand-Foot Syndrome (ranging from Mild to Severe). The range of patients who had any Hand-Foot Syndrome during the first 24 weeks of treatment with Tagrisso was between 22% - 41%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Hand-Foot Syndrome During the First 24 Weeks on Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, showing proportion of patients reporting the severity of hand-foot syndrome at each time point through the first 24 weeks of treatment. For example, at week 2, 30% of patients taking Tagrisso reported hand-foot syndrome (ranging from mild to severe).

All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Hand-Foot Syndrome That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Hand-Foot Syndrome During the First 24 Weeks on Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, summarizing the percentage of patients by worst reported hand-foot syndrome during the first 24 weeks of the clinical trial. In the Tagrisso arm, None (29%), Mild (38%), Moderate (24%), Severe (5%) and Very severe (4%). In the chemotherapy arm, None (34%), Mild (51%), Moderate (11%), Severe (0%) and Very severe (4%).

Patients with at least one on-treatment Hand-Foot Syndrome score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Hand-Foot Syndrome Before Treatment:

For patients that did not report Hand-Foot Syndrome before treatment, Figure 3 shows the percentage of patients reporting the severity of their Hand-Foot Syndrome between weeks 1 and 24.

Figure 3. Patient-Reported Hand-Foot Syndrome During the First 24 Weeks on Treatment: Patients Without Hand-Foot Syndrome Before Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no hand-foot syndrome before treatment. The bar charts show the proportion of patients reporting severity of hand-foot syndrome at each time point through 24 weeks. For example, at week 2, 16% of patients taking Tagrisso reported mild hand-foot syndrome.

All responses from patients who did not report Hand-Foot Syndrome before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Hand-Foot Syndrome That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Hand-Foot Syndrome Before Treatment:

Figure 4. Worst Patient-Reported Hand-Foot Syndrome During the First 24 Weeks on Treatment: Patients Without Hand-Foot Syndrome Before Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no hand-foot syndrome before treatment. The pie charts summarize the percentage of patients by worst reported hand-foot syndrome. In the Tagrisso arm, None (38%), Mild (43%), Moderate (13%), Severe (4%) and Very severe (2%). In the chemotherapy arm, None (48%), Mild (39%), Moderate (13%) Severe (0%) and Very severe (0%).

Patients who had no Hand-Foot Syndrome before treatment and at least one on-treatment Hand-Foot Syndrome score were included in the analysis. Tagrisso (N=55), Chemotherapy (N=31).

Back to Top